CO4810374A1 - NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY - Google Patents

NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Info

Publication number
CO4810374A1
CO4810374A1 CO98060225A CO98060225A CO4810374A1 CO 4810374 A1 CO4810374 A1 CO 4810374A1 CO 98060225 A CO98060225 A CO 98060225A CO 98060225 A CO98060225 A CO 98060225A CO 4810374 A1 CO4810374 A1 CO 4810374A1
Authority
CO
Colombia
Prior art keywords
compounds
mammal
independently
compound
case
Prior art date
Application number
CO98060225A
Other languages
Spanish (es)
Inventor
Don E Griswold
Iv Siegfried B Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4810374A1 publication Critical patent/CO4810374A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Abstract

Un método de tratamiento de prurito en un mamífero que necesitade ello, que comprende administrar a dicho mamífero una cantidad eficaz de un compuesto de un inhibidor de PDE4 , distinto de CP 80633. El método según la reivindicación 1, en el que el inhibidor de PDE4 es un compuesto de la fórmula: en la que: R1 y R2 , independientemente en cada caso, representan alquilo o -(CH2 )m -A; m representa cero o el número entero 1, 2 ó 3; A representa un radical hidrocarbonado cíclico no sustituido o sustituido; R3 representa un átomo de halógeno, un grupo nitro o un grupo -NR4 R5 ; R4 y R5 , independientemente en cada caso, representan hidrógeno, alquilo o alquilcarbonilo, o R4 y R5 junto con el nitrógeno al que están unidos forman un anillo heterocíclico opcionalmente sustituido; y sus sales farmacéuticamente aceptables.A method of treating pruritus in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of a PDE4 inhibitor, other than CP 80633. The method according to claim 1, wherein the PDE4 inhibitor it is a compound of the formula: wherein: R1 and R2, independently in each case, represent alkyl or - (CH2) m -A; m represents zero or the integer 1, 2 or 3; A represents an unsubstituted or substituted cyclic hydrocarbon radical; R3 represents a halogen atom, a nitro group or a -NR4 R5 group; R4 and R5, independently in each case, represent hydrogen, alkyl or alkylcarbonyl, or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; and its pharmaceutically acceptable salts.

CO98060225A 1997-10-17 1998-10-16 NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY CO4810374A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17

Publications (1)

Publication Number Publication Date
CO4810374A1 true CO4810374A1 (en) 1999-06-30

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98060225A CO4810374A1 (en) 1997-10-17 1998-10-16 NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Country Status (18)

Country Link
EP (1) EP1030666A4 (en)
JP (1) JP2001520196A (en)
KR (1) KR20010031149A (en)
CN (1) CN1306426A (en)
AR (1) AR015966A1 (en)
AU (1) AU740875B2 (en)
BR (1) BR9814080A (en)
CA (1) CA2306985A1 (en)
CO (1) CO4810374A1 (en)
CZ (1) CZ20001376A3 (en)
HU (1) HUP0003792A3 (en)
IL (1) IL135581A0 (en)
NO (1) NO20001847L (en)
NZ (1) NZ503551A (en)
PL (1) PL341062A1 (en)
TR (1) TR200001040T2 (en)
WO (1) WO1999020280A1 (en)
ZA (1) ZA989450B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365443A1 (en) 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CA2436535A1 (en) 2001-01-31 2002-08-08 Prizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
WO2002060896A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
EP1647274A4 (en) * 2003-07-17 2008-12-10 Ono Pharmaceutical Co Remedy for pruritus comprising piperidine derivative as the active ingredient
JP2005187458A (en) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd Itchiness-treating agent consisting of cilomilast or its salt as active ingredient
WO2005053672A1 (en) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
KR101100601B1 (en) * 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 Novel compounds
JP2008137892A (en) * 2005-03-04 2008-06-19 Eisai Co Ltd Antipruritic agent
JP2009504592A (en) 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション Xanthine derivatives as selective HM74A agonists
TWI404709B (en) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
MX2008010774A (en) 2006-02-21 2008-09-01 Eisai R&D Man Co Ltd 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative.
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd Crystal, amorphous form and salt of methyl n-ý3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl¨terephthalamic acid
JP5060561B2 (en) 2007-08-17 2012-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 New topical preparation
JP5043945B2 (en) 2007-08-17 2012-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing quinazoline derivative
EP2727594B1 (en) * 2011-06-28 2017-12-20 Mitsubishi Tanabe Pharma Corporation Naphtalene compounds to treat itch
SG10201907026RA (en) 2015-01-30 2019-09-27 Shanton Pharma Co Ltd Prevention or Treatment of Uratic or Gouty Diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011260A1 (en) * 1990-12-21 1992-07-09 Beecham Group Plc Xanthine derivatives
JP4141501B2 (en) * 1996-03-26 2008-08-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel 6-substituted phenanthridine
AU2892397A (en) * 1996-05-15 1997-12-05 Byk Gulden Novel imidazopyridines
PT968211E (en) * 1997-03-07 2004-01-30 Altana Pharma Ag TETRAZOLE DERIVATIVES
PL336464A1 (en) * 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
JP2002502403A (en) * 1997-06-03 2002-01-22 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Benzonaphthyridine

Also Published As

Publication number Publication date
BR9814080A (en) 2000-09-26
NO20001847D0 (en) 2000-04-10
CZ20001376A3 (en) 2002-06-12
AU1093899A (en) 1999-05-10
NZ503551A (en) 2002-05-31
EP1030666A1 (en) 2000-08-30
JP2001520196A (en) 2001-10-30
CN1306426A (en) 2001-08-01
NO20001847L (en) 2000-04-10
WO1999020280A1 (en) 1999-04-29
ZA989450B (en) 1999-04-19
CA2306985A1 (en) 1999-04-29
IL135581A0 (en) 2001-05-20
TR200001040T2 (en) 2001-01-22
PL341062A1 (en) 2001-03-26
AR015966A1 (en) 2001-05-30
AU740875B2 (en) 2001-11-15
HUP0003792A3 (en) 2001-12-28
KR20010031149A (en) 2001-04-16
HUP0003792A2 (en) 2001-10-28
EP1030666A4 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
CO4810374A1 (en) NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY
AR044719A1 (en) DERIVATIVES OF PHENYL AND PIRIDINYL, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
AR010331A1 (en) COMPOUNDS DERIVED FROM 6-PHENYLPYRIDYL-2-AMINE USEFUL AS INHIBITORS US, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS OF TREATMENT USING THESE COMPOUNDS.
CO5140087A1 (en) DERIVATIVES OF 3-PHENYL-PYRIDINE YOUR SYNTHESIS PROCEDURE AND MEDICINES CONTAINING THEM
AR029614A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
AR002746A1 (en) PIRIMIDINE-DERIVED COMPOUNDS CONDENSED WITH A HETERO-CYCLIC RING AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS.
ECSP088550A (en) NEW COMPOUNDS THAT ARE ERK INHIBITORS
AR035548A1 (en) ORGANIC COMPOUNDS
CO5050332A1 (en) FUNGICIDE COMPOSITIONS THAT INCLUDE 2-METOXIBENZOPHENONES
ATE152719T1 (en) CHINOLYLBENZOFURAN DERIVATIVES AS LEUCOTRIEN ANTAGONISTS
ES2039242T3 (en) A PROCEDURE FOR THE PREPARATION OF NEW PIPERIDINE DERIVATIVES.
DK1001930T3 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
CO5160347A1 (en) CARBAMIC ACID DERIVATIVES
ATE280763T1 (en) MATRIX METALLOPROTEINASE INHIBITORS
CO4920225A1 (en) 2-AMINO-6- (4-PHENOXI-2-SUBSTITUTED) -PIRIDINES SUBSTITUTED
ATE120955T1 (en) BENZYLIDENE-MALONONITRILE DERIVATIVES FOR INHIBITING PROLIFERATIVE PROCESSES IN MAMMAL CELLS.
SE0101579D0 (en) New compounds
MX9302957A (en) XANTINA COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR045768A1 (en) CEFEM COMPOUNDS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
CO4950553A1 (en) 7-TETRAHYDROISOKINOLIN COMPOUNDS AND PROCEDURE FOR THE PREPARATION
AR012603A1 (en) PROTEASE INHIBITOR, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT; AND SYNTHESIS INTERMEDIARIES
YU46787B (en) HETEROARYL 3-OXO-PROPANE-NITRILE DERIVATIVES AND PROCESS FOR THEIR OBTAINING
AR016644A1 (en) COMPOUNDS OF 2-AMINOPIRIDINAS WITH ALCOXI RAMIFIED SUBSTITUTES, PHARMACEUTICAL COMPOSITION AND USE FOR THE MANUFACTURE OF MEDICINES
PE20011134A1 (en) 4-FLUORALKYL-2H-BENZOPYRANES WITH ANTIESTROGENIC EFFECT, METHOD FOR OBTAINING THEM, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM AND THEIR USE TO OBTAIN MEDICINES
NO964698D0 (en) Bicyclic amine derivatives as inhibitors of nitric oxide synthetase